医学
间质性肺病
肺病
肺
内科学
重症监护医学
病理
作者
Jonathan A. Rose,Ann-Marcia Tukpah,Claire C. Cutting,Noriaki Wada,Mizuki Nishino,Matthew Moll,S. Kalra,Bina Choi,David A. Lynch,Benjamin A. Raby,Iván O. Rosas,Raúl San Jośe Estépar,George R. Washko,Edwin K. Silverman,Michael H. Cho,Hiroto Hatabu,Rachel K. Putman,Gary M. Hunninghake
标识
DOI:10.1164/rccm.202402-0313oc
摘要
Rationale: Some with interstitial lung abnormalities (ILA) have suspected interstitial lung disease (ILD), a subgroup with adverse outcomes. Rates of development and progression of suspected ILD and their effect on mortality are unknown. Objectives: To determine rates of development and progression of suspected ILD and assess effects of individual ILD and progression criteria on mortality. Methods: Participants from COPDGene were included. ILD was defined as ILA and fibrosis and/or FVC <80% predicted. Prevalent ILD was assessed at enrollment, incident ILD and progression at 5-year follow-up. CT progression was assessed visually and FVC decline as relative change. Multivariable Cox regression tested associations between mortality and ILD groups. Results: Of 9,588 participants at enrollment, 267 (2.8%) had prevalent ILD. Those with prevalent ILD had 52% mortality after median 10.6 years, which was higher than ILA (33%; HR=2.0; p<0.001). The subgroup of prevalent ILD with fibrosis only had worse mortality (59%) than ILA (HR=2.2; p<0.001). 97 participants with prevalent ILD completed 5-year follow-up: 32% had stable CT and relative FVC decline <10%, 6% FVC decline ≥10% only, 39% CT progression only, and 22% both CT progression and FVC decline ≥10%. Mortality rates were 32%, 50%, 45%, and 46% respectively; those with CT progression only had worse mortality than ILA (HR=2.6; p=0.005). At 5-year follow-up, incident ILD occurred in 168/4,843 participants without prevalent ILD and had worse mortality than ILA (HR=2.5; p<0.001). Conclusion: Rates of mortality and progression are high among those with suspected ILD in COPDGene; fibrosis and radiologic progression are important predictors of mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI